Author

Hearn Jay Cho

Observed names: HEARN JAY CHO, Hearn Jay Cho, Hearn Cho, Hearn J Cho, Hearn J. Cho

Institutions: Multiple Myeloma Research Foundation, Tisch Hospital, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

Observed institutions: National Institutes of Health, Mount Sinai Hospital, Hackensack University Medical Center, NewYork–Presbyterian Hospital, George Washington University, Ludwig Cancer Research, Cornell University, Multiple Myeloma Research Foundation, University of California San Diego, NYU Langone Health, National Heart, Lung, and Blood Institute, Tisch Hospital, Ludwig Cancer Research, Weill Cornell Medicine, Tisch Cancer Institute, Weill Cornell Medical Center, New York University, Rockefeller University, Icahn School of Medicine at Mount Sinai

ORCID: 0000-0003-4481-5757

Observed ORCID: 0000-0003-4481-5757

OpenAlex ID: A5002010987

Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages

1992 · Qiao-wen Xie, Hearn J. Cho, et al. · Science · 1,888

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

2000 · Hearn Jay Cho, Kenji Takabayashi, et al. · Nature Biotechnology · 258

A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6

2006 · Linda B. Baughn, Maurizio Di Liberto, et al. · Cancer Research · 224

PDF

Rituximab in the treatment of acquired factor VIII inhibitors

2002 · Adrian Wiestner, Hearn J. Cho, et al. · Blood · 215

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

2007 · Ruben Niesvizky, David S. Jayabalan, et al. · Blood · 184

The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation

2005 · Achim A. Jungbluth, Scott Ely, et al. · Blood · 182

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

2016 · Rachid C. Baz, Thomas G. Martin, et al. · Blood · 159

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

2020 · Bo Wang, Oliver Van Oekelen, et al. · Journal of Hematology & Oncology · 143

PDF

IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

2023 · Guido Lancman, Kian Parsa, et al. · Blood Cancer Discovery · 139

PDF

Mutually Exclusive Cyclin-Dependent Kinase 4/Cyclin D1 and Cyclin-Dependent Kinase 6/Cyclin D2 Pairing Inactivates Retinoblastoma Protein and Promotes Cell Cycle Dysregulation in Multiple Myeloma

2005 · Scott Ely, Maurizio Di Liberto, et al. · Cancer Research · 115

IFN-αβ Promote Priming of Antigen-Specific CD8+ and CD4+ T Lymphocytes by Immunostimulatory DNA-Based Vaccines

2002 · Hearn Jay Cho, Tomoko Hayashi, et al. · The Journal of Immunology · 113

Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

2022 · Oliver Van Oekelen, Karthik Nath, et al. · Blood · 105

PDF

Immunostimulatory DNA Is a Potent Mucosal Adjuvant

1998 · Anthony A. Horner, Arash Ronaghy, et al. · Cellular Immunology · 101

Bispecific Antibodies in Multiple Myeloma: Present and Future

2021 · Guido Lancman, Dahniel L. Sastow, et al. · Blood Cancer Discovery · 99

PDF

Combination Strategies to Enhance Antitumor ADCC

2012 · Holbrook E Kohrt, Roch Houot, et al. · Immunotherapy · 97

Inducible Nitric Oxide Synthase Requires Both the Canonical Calmodulin-binding Domain and Additional Sequences in Order to Bind Calmodulin and Produce Nitric Oxide in the Absence of Free Ca2+

1996 · Jia Ruan, Qiao-wen Xie, et al. · Journal of Biological Chemistry · 97

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

2024 · Sheri Skerget, Daniel Penaherrera, et al. · Nature Genetics · 92

PDF

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

2022 · Josh N. Vo, Yi-Mi Wu, et al. · Nature Communications · 91

PDF

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

2019 · Deepak Perumal, Naoko Imai, et al. · Clinical Cancer Research · 90

MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin

2011 · Tricia Nardiello, Achim A. Jungbluth, et al. · Clinical Cancer Research · 89

2021 · Sherry Bhalla, David T. Melnekoff, et al. · Science Advances · 72

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

2018 · Guido Lancman, Suzanne Arinsburg, et al. · Frontiers in Immunology · 64

PDF

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

2020 · Noffar Bar, Federica Costa, et al. · JCI Insight · 61

PDF

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma

2017 · Ajai Chari, Hearn J. Cho, et al. · Blood Advances · 60

PDF

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

2020 · Shashidhar S. Jatiani, Adolfo Aleman, et al. · Clinical Lymphoma Myeloma & Leukemia · 56

Works count: 394

Citation count: 6,463

H-index: 37

I10-index: 79